Company Description
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States.
The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.
The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers.
It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Feb 21, 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Douglas Murphy-Chutorian |
Contact Details
Address: 2340-2348 Walsh Avenue, Suite 2344 Santa Clara, California 95051 United States | |
| Phone | 877 774 4211 |
| Website | semlerscientific.com |
Stock Details
| Ticker Symbol | SMLR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001554859 |
| CUSIP Number | 81684M104 |
| ISIN Number | US81684M1045 |
| Employer ID | 26-1367393 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas Murphy-Chutorian M.D. | Chief Executive Officer, President and Director |
| Eric H. Semler | Executive Chairman of the Board |
| Renae Cormier | Chief Financial Officer, Head of Corporate Communications and Business Strategy and Secretary |
| Dr. Herbert J. Semler F.A.C.C., F.A.C.P, F.A.H., F.S.C.A.I., J.S., M.D. | Founder and Chairman Emeritus |
| Shane Reid | Chief Technology Officer |
| Cindy Guinasso | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | SCHEDULE 13G | Filing |
| Aug 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 4, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | 8-K | Current Report |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 17, 2025 | ARS | Filing |
| Jul 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 17, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 17, 2025 | 8-K | Current Report |
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |